A detailed history of Fil LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fil LTD holds 11,467 shares of APLS stock, worth $352,839. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,467
Previous 11,087 3.43%
Holding current value
$352,839
Previous $425,000 22.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$28.84 - $41.15 $10,959 - $15,637
380 Added 3.43%
11,467 $330,000
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $189,550 - $297,296
4,979 Added 81.52%
11,087 $425,000
Q1 2024

May 13, 2024

BUY
$55.39 - $72.47 $23,873 - $31,234
431 Added 7.59%
6,108 $359,000
Q4 2023

Feb 13, 2024

BUY
$37.14 - $64.82 $210,843 - $367,983
5,677 New
5,677 $339,000
Q3 2021

Nov 15, 2021

SELL
$31.4 - $69.84 $9.7 Million - $21.6 Million
-309,031 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$40.9 - $64.9 $59,550 - $94,494
1,456 Added 0.47%
309,031 $19.5 Million
Q1 2021

May 14, 2021

SELL
$40.8 - $57.39 $472,423 - $664,518
-11,579 Reduced 3.63%
307,575 $13.2 Million
Q4 2020

Feb 08, 2021

BUY
$30.79 - $57.2 $5.85 Million - $10.9 Million
189,835 Added 146.8%
319,154 $18.3 Million
Q3 2020

Nov 13, 2020

SELL
$25.89 - $33.65 $22 Million - $28.6 Million
-850,397 Reduced 86.8%
129,319 $3.9 Million
Q2 2020

Aug 13, 2020

SELL
$24.8 - $38.49 $3.09 Million - $4.8 Million
-124,633 Reduced 11.29%
979,716 $32 Million
Q1 2020

May 14, 2020

SELL
$17.91 - $44.33 $5.19 Million - $12.9 Million
-289,936 Reduced 20.79%
1,104,349 $29.6 Million
Q4 2019

Feb 07, 2020

BUY
$22.1 - $30.8 $6.57 Million - $9.15 Million
297,083 Added 27.08%
1,394,285 $42.7 Million
Q3 2019

Nov 13, 2019

BUY
$24.09 - $32.18 $26.4 Million - $35.3 Million
1,097,202 New
1,097,202 $26.4 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.38B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Fil LTD Portfolio

Follow Fil LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.